Top Follow App Download BETTER
Roseanne Dumpe
Using social media is an easy and effective way to instantly and directly promote your Rainforest Alliance Certified products to consumers around the world and engage with your followers on why your company cares about sustainability.
Important: Unless your profile is set to restricted, other Google Maps users will be able to review who you're following and who follows you on your profile. If your profile is set to restricted, only people following you can review the list of who you're following and who follows you.
Once you follow a Maps contributor or verified account, you'll find their reviews, ratings, photos, and other public contributions to Google Maps in the "Following" tab. You can follow a maximum of 10,000 contributors or accounts.
We also recommend people in the recommendation carousel based on interactions. To limit who can follow you and which people you get recommended to, change your profile visibility. If you set your profile to Restricted, your profile isn't recommended to others and people can't see who you're following. Learn how to change your profile visibility.
Following shows all the sites you follow, such as your team site or a site from another group you work with. To follow a SharePoint site, go to where it is, and select the star next to the site's name.
Digital Technology. to indicate interest in and establish a connection with (a social media account) so as to keep up with the online content it publishes, as posts, images, or videos: I follow my friends and some celebrities on Twitter, but nobody who tweets political stuff.
Making language models bigger does not inherently make them better at following a user's intent. For example, large language models can generate outputs that are untruthful, toxic, or simply not helpful to the user. In other words, these models are not aligned with their users. In this paper, we show an avenue for aligning language models with user intent on a wide range of tasks by fine-tuning with human feedback. Starting with a set of labeler-written prompts and prompts submitted through a language model API, we collect a dataset of labeler demonstrations of the desired model behavior, which we use to fine-tune GPT-3 using supervised learning. We then collect a dataset of rankings of model outputs, which we use to further fine-tune this supervised model using reinforcement learning from human feedback. We call the resulting models InstructGPT. In human evaluations on our prompt distribution, outputs from the 1.3B parameter InstructGPT model are preferred to outputs from the 175B GPT-3, despite having 100x fewer parameters. Moreover, InstructGPT models show improvements in truthfulness and reductions in toxic output generation while having minimal performance regressions on public NLP datasets. Even though InstructGPT still makes simple mistakes, our results show that fine-tuning with human feedback is a promising direction for aligning language models with human intent.
The CDC and FDA require additional information on selected VAERS reports for the public health purpose of helping to ensure the safety of U.S. licensed vaccines. You or your health care provider may be contacted for follow-up information by VAERS staff after your report is received. These selected reports are followed up by a team of health care professionals to obtain additional information (such as medical records and autopsy reports) to provide as complete a picture of the case as possible.
Background: A recently published randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychotherapy in participants with cancer-related psychiatric distress. Results suggested that psilocybin-assisted psychotherapy facilitated improvements in psychiatric and existential distress, quality of life, and spiritual well-being up to seven weeks prior to the crossover. At the 6.5-month follow-up, after the crossover, 60-80% of participants continued to meet criteria for clinically significant antidepressant or anxiolytic responses.
Methods: The present study is a long-term within-subjects follow-up analysis of self-reported symptomatology involving a subset of participants that completed the parent trial. All 16 participants who were still alive were contacted, and 15 participants agreed to participate at an average of 3.2 and 4.5 years following psilocybin administration.
Results: Reductions in anxiety, depression, hopelessness, demoralization, and death anxiety were sustained at the first and second follow-ups. Within-group effect sizes were large. At the second (4.5 year) follow-up approximately 60-80% of participants met criteria for clinically significant antidepressant or anxiolytic responses. Participants overwhelmingly (71-100%) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.
The Inter-American Commission on Human Rights (IACHR) makes recommendations to the Member States of the Organization of American States (OEA) in order to promote due respect for human rights. This is one of the functions mandated to the Commission to promote the observance and defense of human rights in the Americas. Within the framework of its petition and case system, the Commission adopts and follows up on the recommendations in published merits reports; the decisions in the reports which approve friendly settlement agreements between Member States and petitioners before the inter-American human rights system; and, the decisions in the resolutions that grant or extend precautionary measures to persons or groups in situations of imminent risk. Within the framework of its monitoring system, the Commission adopts and follows up on the recommendations published in thematic reports, the Annual Report of the IACHR and in reports on the human rights situations in countries. Throughout its history, the Commission has consolidated its practice of following up on its reports by producing specific follow-up reports that aim to assess compliance with previously issued recommendations.
In accordance with its 2017-2021 Strategic Plan, the IACHR created and put into operation in 2018 the Follow-up of Recommendations Section, which is structurally linked to the Assistant Executive Secretariat for the Monitoring, Promotion and Technical Cooperation in Human Rights, and which has the function of organizing the follow-up work of the entire Executive Secretariat of the IACHR in an integral, transversal and coordinated manner. The Section is responsible for coordinating the follow-up of the recommendations issued by the IACHR through its various mechanisms and tools (Executive Order SG/OAS No. 17/06, Annex I, D, 7).
You can choose to follow specific records, or unfollow records that you're already receiving notifications about. By default, every user is set to automatically follow records that they are the owner of.
We understand that our BMT survivors may feel anxious about COVID-19. We are taking measures to make our clinic visits safe through additional screening and COVID-19 testing. We are following all guidance about personal protective equipment and additional cleaning and are confident that our actions are making a visit to the clinic safe for patients and staff. There are new practices in place that you will be asked to follow if you have an appointment.
Fred Hutch's Long-Term Follow-Up (LTFU) program provides life-long monitoring and care for patients following a bone-marrow or stem-cell transplant. Our physicians and researchers work in partnership with a patient's personal doctor to resolve medical problems and gather information for research. This information is used to develop improved strategies for preventing and treating the long-term effects of transplantation, and to educate patients about post-transplant problems.
Your follow-up care plan, along with a summary of your cancer treatment, is part of what is called a survivorship care plan. This plan will have all the details that you and your doctor should discuss to ensure that you get regular care after your treatment ends.
Once your cancer treatment ends, you should receive a follow-up cancer care plan from your oncologist or someone on your treatment team. A follow-up care plan is a summary of your treatment, along with recommendations for your cancer care after treatment ends. Your plan may also include suggestions to help meet other needs, such as emotional, social, or financial issues.
Choose which doctor to see after treatment. For follow-up cancer care, you may see the same doctor who treated you for cancer or you may see another health care provider, such as one who specializes in follow-up care for cancer survivors. Or you may decide to go to your primary care doctor. You can discuss which doctor(s) to see with your health care team.
You might find it helpful to write these questions down. When you meet with the doctor or follow-up care specialist, you can take notes or record your talks to refer to later. Talk about any concerns you have related to your follow-up care plan.
At these visits, you may have a physical exam along with blood tests and other necessary tests and procedures. Which tests you receive and how often you receive them will be based on what your doctor thinks is best for you when creating your follow-up care plan.
Some cancer centers and hospitals have programs that specialize in long-term follow-up care for cancer survivors. Many NCI-Designated Cancer Centers and large community treatment centers offer some form of survivorship program or clinic for adults who have been treated for cancer. Also, the cancer education website OncoLink has a searchable database of survivorship clinics across the United States.
Some cancer treatments can cause problems that may not show up for months or years after treatment. These problems, called late effects, are specific to certain types of treatments and the dose received. When you discuss follow-up care with your doctor, they should talk with you about which late effects to watch for. Early medical attention can help reduce problems that may come from late effects. See Late Side Effects of Cancer Treatment to learn more.
df19127ead